Business Context and Reporting Period
Company: UBS Group AG
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Fourth Quarter and Full Year ended December 31, 2015
Filing Date: February 2, 2016
UBS reported a strong recovery in profitability for 2015, driven by cost discipline and improved performance across business divisions despite challenging market conditions. The Group achieved its full-year adjusted return on tangible equity target of around 10%, reaching 13.7%.
Key Financial Metrics
| Metric | Q4 2015 | Full Year 2015 | Full Year 2014 |
|---|---|---|---|
| Net Profit (Attributable to Shareholders) | CHF 949 million | CHF 6.2 billion | CHF 3.5 billion |
| Diluted Earnings Per Share (EPS) | CHF 0.25 | CHF 1.64 | CHF 0.91 |
| Operating Income | CHF 6.8 billion | CHF 30.6 billion | CHF 28.0 billion |
| Operating Expenses | CHF 6.5 billion | CHF 25.1 billion | CHF 25.6 billion |
| Cost/Income Ratio (Adjusted) | 88.2% | 81.8% | 91.0% |
| Return on Tangible Equity (Adjusted) | 11.4% | 13.7% | 8.2% |
| CET1 Capital Ratio (Fully Applied) | 14.5% | 14.5% | 13.4% |
| Leverage Ratio (Fully Applied) | 5.3% | 5.3% | 4.1% |
| Liquidity Coverage Ratio | 128% | 128% | 123% |
Material Changes vs. Prior Period
- Profit Surge: Full-year net profit increased 79% year-over-year to CHF 6.2 billion. This was significantly aided by a net tax benefit of CHF 715 million in Q4, primarily due to the upward revaluation of deferred tax assets.
- Divisional Performance:
- Wealth Management: Achieved its best annual pre-tax profit since 2008 (CHF 2.8 billion adjusted). However, Q4 saw net new money outflows of CHF 3.4 billion due to client deleveraging and cross-border outflows.
- Wealth Management Americas: Recorded record operating income and net new money of USD 21.4 billion for the full year.
- Investment Bank: Delivered an adjusted pre-tax profit of CHF 2.3 billion, with an adjusted return on attributed equity of 31%.
- Personal & Corporate Banking: Posted its best adjusted pre-tax profit since 2010 (CHF 1.7 billion).
- Balance Sheet Reduction: Total assets decreased to CHF 943 billion, driven by reductions in positive replacement values and collateral trading assets.
Guidance, Outlook, and Risks
Dividend Proposal: The Board intends to propose a total dividend of CHF 0.85 per share (CHF 0.60 ordinary + CHF 0.25 special) to be paid from capital contribution reserves.
Outlook: Management expects continued headwinds from negative market performance, low interest rates, and a strong Swiss franc. Proposed changes to the Swiss "too big to fail" framework are expected to cause substantial ongoing interest costs.
Risks and Contingencies:
- Regulatory & Litigation: UBS faces ongoing investigations and settlements regarding foreign exchange manipulation, LIBOR benchmark rates, and RMBS sales. Provisions for litigation and regulatory matters totaled CHF 365 million in Q4.
- Energy Sector Exposure: Net credit loss expense increased in the Investment Bank due to energy sector exposures, with total net lending exposure to oil and gas at CHF 6.1 billion.
- Accounting Changes: UBS expects to record net foreign currency translation losses of approximately CHF 250 million in the first half of 2016 due to the reclassification of gains/losses from equity to the income statement.
Investor Verification Checklist
- Tax Benefit Sustainability: Verify the one-time nature of the CHF 715 million Q4 tax benefit and its impact on future effective tax rates (forecasted 22-25% for 2016).
- Dividend Source: Confirm the payment of dividends from capital contribution reserves and the implications for future capital return policies.
- Regulatory Costs: Assess the potential financial impact of the new Swiss "too big to fail" regulations and ongoing litigation settlements (e.g., FX, LIBOR, RMBS).
- Wealth Management Flows: Monitor the trend of net new money outflows in Wealth Management and the impact of client deleveraging on future fee income.
- Capital Ratios: Track the fully applied CET1 ratio (14.5%) and leverage ratio (5.3%) against regulatory minimums and internal targets.